TOBI

Toby is a health technology company dedicated to revolutionizing early disease detection through non-invasive, AI-powered diagnostics. The company's flagship product is a urine-based test kit designed for the early detection of prostate cancer, leveraging advanced spectroscopy and computational algorithms to identify volatile organic compounds (VOCs) and other biomarkers. By providing a simpler, more accessible alternative to traditional screening methods, Toby aims to improve patient outcomes through earlier intervention. Founded in 2023 and headquartered in San Francisco, the company has gained recognition through participation in prestigious programs like the Mayo Clinic and ASU MedTech Accelerator.